Athira Pharma, Inc.

NASDAQ:ATHA

0.31 (USD) • At close May 30, 2025
Bedrijfsnaam Athira Pharma, Inc.
Symbool ATHA
Munteenheid USD
Prijs 0.313
Beurswaarde 12,200,750
Dividendpercentage 0%
52-weken bereik 0.22 - 3.67
Industrie Biotechnology
Sector Healthcare
CEO Dr. Mark J. Litton M.B.A., MBA, Ph.D.
Website https://www.athira.com

An error occurred while fetching data.

Over Athira Pharma, Inc.

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the

Vergelijkbare Aandelen

Fulcrum Therapeutics, Inc. logo

Fulcrum Therapeutics, Inc.

FULC

6.875 USD

BioXcel Therapeutics, Inc. logo

BioXcel Therapeutics, Inc.

BTAI

1.18 USD

Heron Therapeutics, Inc. logo

Heron Therapeutics, Inc.

HRTX

1.88 USD

HilleVax, Inc. logo

HilleVax, Inc.

HLVX

1.87 USD

Absci Corporation logo

Absci Corporation

ABSI

2.65 USD

ALX Oncology Holdings Inc. logo

ALX Oncology Holdings Inc.

ALXO

0.486 USD

C4 Therapeutics, Inc. logo

C4 Therapeutics, Inc.

CCCC

1.25 USD

Rigel Pharmaceuticals, Inc. logo

Rigel Pharmaceuticals, Inc.

RIGL

19.2 USD

OraSure Technologies, Inc. logo

OraSure Technologies, Inc.

OSUR

2.88 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)